Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
4. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 2003; 91 (Suppl): 3A—6A.
5. Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003; 89:993—997.
6. Altman R. Risk factors in coronary atherosclerosis athero-inflammation: the meeting point. Thrombosis J 2003; 1:4.
7. Stollberger C, Finsterer J. Role of infectious and immune factors in coronary and cerebrovas-cular arteriosclerosis. Clin Diagn Lab Immunol 2002; 9:207—215.
8. Zebrack JS, Anderson JL. The role in inflammation and infection in the pathogenesis and evaluation of coronary artery disease Curr Cardiol Report 2002; 4: 278—288.
9. Malik AB, Lo SK. Vascular endothelial adhesion molecules and tissue inflammation Lab Invest 1996; 48: 213—229.
10. Cinez DB, Pollak ES, Buck CA., et al. Endothelial cells in physiology an in the patho-physiology of vascular disorders. Blood 1998; 91: 3527—3561.
11. Salogin KV, Nasonov EL, Belenkov Yu.N. The role of endothelial cell in immunopathology. Sov Arch Int Med 1992; 64, 1, 16—24.
12. Muller WA. Leukocyte-endothelial cell interactions in the inflammatory response. Lab Invest 2002; 82: 521—533.
13. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 88: 877—887.
14. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. Am J Med 1999; 107: 85—97.
15. Tailor AN, Granger DG. Role of adhesion molecules in vascular regulation and damage. Curr. Hypertension Reports 2000; 2: 78—83.
16. Ley K, Huo Y. VCAM-1 is critical in atherogenesis. J Clin Invest 2001; 1209—1210.
17. De Catarini. Endothelial dysfunction: common denominators in vascular disease. Curr Opin Lipidol 2000; 11: 9—23.
18. Stenvinket P. Endothelial dysfunction and inflammation — is there a link? Nephrol Dial Transplant 2001; 16: 1968—1971.
19. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular disease. The role of oxidant stress. Circ Res 2002; 87: 840—844.
20. Rackley CE. Endothelial dysfunction. UpToDates 2002; 10: 2.
21. Verma S. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105: 546—549.
22. Al Suwaidi J, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial disfunction. Circulation 2000; 101: 948—954.
23. Batnes PJ, Karin M. Nuclear factor NF-kB: a pivotal transcription factor in chronic inflammatory disease. New Engl J Med 1997; 336: 1066—1071.
24. Baldwin ASJ. The transciption factor NF-kB and human disease. J Clin Invest 2001; 107: 3—6.
25. Valen G, Yan ZQ, Hansson GK: Nuclear factor kappa-B and the heart. JAm Coll Cardiol 2001; 38: 307—314.
26. Collins T, Cybulsky MI. NF-kB: pivotal mediator or innocent bystender in atherogenesis? J Clin Invest 2001; 107: 255—264.
27. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs: an overview. In. Selective COX-2 inhibitors. Pharmacology, clinical effects and therapeutic potential. Ed. J. Vane, J. Botting. Kluwer Academic Publisher 1997; 1— 17.
28. Davidge ST. Prostaglandin H synthase and vascular function. Circ Res 2001; 89: 650—660.
29. Belton O, Fitzgerald DJ. Cycloxygenase isoform and atherosclerosis. Expert reviews in molecularmedicine. http.//www.eexpertrexiews.org/.
SHS-OOO4.qxd 21.11.2006 16:56 Page 145
45
ГЛАВА 6. Иммунные механизмы атеросклероза
30. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296: 539—541.
31. Sadoshima J. Cytokine action of angiotensin II. Circ Res 2000; 86:1187—1189.
32. Brasier AR, Recinos A III, Eledsiri MS. Vascular inflammation and the rennin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257—1266.
33. Suzuki Y, Ruiz-Ortega M, Gomez-Guerrero C, et al. Angiotensin II, the immune system and renal disease: another road for RAS? Nephrol Dial Transplant 2—3; 18: 1423—1426.
34. Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35: 881—900.
35. Luft FC. Angiotensin II, the AT2 receptor, and nuclear factor-kB activation. Kidney Int 2002; 61: 2272—2273.
36. Ruiz-Ortega M. Lorenzo O, Ruperez M, et al. Angiotensin II activates nuclear transcription factor kB through AT1 and AT2 in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000; 86: 1266—1272.
37. Wulf D. Free radicals in the Physiological Control of Cell Function. Physiol Rew 2002; 82 : 47—95.
38. Nedelikovic ZS, Gokce N, Loscalzo J. Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J 2003; 79: 195—200.
39. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine (third edition), 2000; Oxford University Press.
40. Welch GN, Koscalzo J. Homocystein and atherothrombosis. N Engl J Med 1998; 338: 1042—1050.
41. The homocystein studies collaboration. Homocystein and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288: 2015—2022.
